Study summary · research use only
The Role of Cathelicidin LL-37 in Cancer Development
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review examines the role of cathelicidin LL-37 in cancer development. The abstract describes LL-37 as a C-terminal peptide released from the 18 kDa human cathelicidin protein (hCAP18) and links chronic infection, inflammation, tissue injury and regeneration, involving LL-37's antibacterial and immunomodulatory functions, to neoplastic growth. It states evidence that LL-37 can promote or inhibit tumor growth in tissue-specific, receptor-dependent ways, with overexpression associated with development of ovarian, lung and breast cancers and with suppression of tumorigenesis in colon and gastric cancer. The authors summarize current views on how LL-37 contributes to immunity, pathophysiology and cell signaling in malignant tumor growth.
Abstract
LL-37 is a C-terminal peptide proteolytically released from 18 kDa human cathelicidin protein (hCAP18). Chronic infections, inflammation, tissue injury and tissue regeneration are all linked with neoplastic growth, and involve LL-37 antibacterial and immunomodulatory functions. Such a link points to the possible involvement of LL-37 peptide in carcinogenesis. An increasing amount of evidence suggests that LL-37 can have two different and contradictory effects--promotion or inhibition of tumor growth. The mechanisms are tissue-specific, complex, and depend mostly on the ability of LL-37 to act as a ligand for different membrane receptors whose expression varies on different cancer cells. Overexpression of LL-37 was found to promote development and progression of ovarian, lung and breast cancers, and to suppress tumorigenesis in colon and gastric cancer. This review explores and summarizes the current views on how LL-37 contributes to immunity, pathophysiology and cell signaling involved in malignant tumor growth.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.